OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE) announced that partner Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) has received Health Canada approval for Semaglutide Injection, a generic version of Ozempic®.
OneSource Specialty Pharma served as the CDMO partner, providing scale-up and commercial manufacturing from its US FDA approved facility in Bengaluru to ensure a reliable supply.
Mr. Neeraj Sharma, CEO & MD, OneSource Specialty Pharma, said: “We are pleased to announce that our partner Dr. Reddy’s has received approval from Health Canada for Semaglutide Injection, a generic version of Ozempic®. This approval further strengthens our collaboration, combining Dr. Reddy’s expertise in peptide development with OneSource’s CDMO capabilities.”
The approval marks another milestone for India’s growing peptide manufacturing capabilities in the global generics market.
